Alabduljabbar, K., Bonanos, E., Miras, A
Compounded semaglutide typically has a Beyond-Use Date (BUD) of 30 to 90 days, as determined by the compounding pharmacy
Most patients experience the greatest symptoms during initial treatment and dose increases, with improvement after dose stabilization
Through our personalized assessment, we can identify these potential hurdles before they become problems
The doses of the other antihyperglycemic agents that are being administered concomitantly will not be adjusted during the study period
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes